Development of advanced therapies in cancer using a high loaded targeted delivery platform

Spirea is responding to challenges faced by the developers of next-generation cancer therapies, by applying its proprietary and proven core polymer platform technology. New classes of innovative pharmaceutical products are being developed to improve the effectiveness and safety of the potent drugs used to treat cancer, through precision medicine. In these techniques the drugs are directed specifically at cancerous cells, while leaving healthy cells untouched. This has the potential to significantly improve patient care, and crucially, reduce side effects. Despite evidence for improved treatment, the number of these products reaching the market has been limited due to technical challenges, along with stability issues. This innovation applies Spirea’s existing proprietary technology of targeted drug delivery, to this new field in cancer therapy. The objective of the project is to generate a powerful new therapy platform using our enabling polymer technology, through technical evaluation, generating experimental evidence, in parallel to product development planning through customer engagement. The results of the project will be that Spirea will establish a platform technology that will create added value for customers, with real potential for growth.